MRVIHealthcare · BiotechnologyThe 8 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. hold a median 12-month price target of $7 — -19.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Maravai Lifesciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (36): The share price moves around a lot.
Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MRVI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −19.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $5.50 → $6.50 |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | $4.50 → $5.50 |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 15 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 12 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 12 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 13 May 2025 | Baird | Maintains | Neutral | — |
| 13 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 25 Mar 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 21 Mar 2025 | UBS | Maintains | Neutral | — |
| 3 Mar 2025 | B of A Securities | Maintains | Buy | — |
| 26 Feb 2025 | Baird | Downgrade | Neutral | — |
| 5 Dec 2024 | Goldman Sachs | Downgrade | Sell | — |
| 14 Nov 2024 | Wolfe Research | Initiates | Peer Perform | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 8 Nov 2024 | RBC Capital | Maintains | Outperform | — |
| 8 Nov 2024 | William Blair | Downgrade | Market Perform | — |
| 8 Oct 2024 | Goldman Sachs | Maintains | Neutral | — |
| 27 Aug 2024 | Wells Fargo | Initiates | Overweight | — |
| 16 Aug 2024 | RBC Capital | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRVI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 11% of US stocks
Cheaper than 18% of US stocks
Cheaper than 95% of US stocks
Higher than 48% of US stocks
Higher than 46% of US stocks
Higher than 50% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 26% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Maravai Lifesciences Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Maravai LifeSciences Holdings, Inc. released its Q2 2026 earnings call transcript, covering the company's second-quarter 2026 financial results and management commentary. The transcript was published via Seeking Alpha.
Why it matters — MRVI watchers would review the earnings call transcript for management's own account of the quarter's financial performance and outlook.
Maravai LifeSciences reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its adjusted EBITDA forecast.
Why it matters — MRVI watchers would care because the company's improved profitability and raised adjusted EBITDA forecast signal stronger underlying financial performance for the year.
Maravai LifeSciences Holdings reported a second-quarter loss of $0.02 per share, narrower than the Zacks Consensus Estimate of a $0.05 loss and improved from a $0.08 loss in the same quarter a year ago.
Why it matters — The improved, better-than-expected quarterly loss may indicate strengthening underlying performance for MRVI watchers.
Maravai LifeSciences reported second-quarter 2026 results with revenue of $51.4 million, a net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million. The company also raised its full-year 2026 Adjusted EBITDA guidance to $33 million to $35 million.
Why it matters — The raised full-year Adjusted EBITDA guidance signals improved expectations for Maravai's performance, offering a key indicator for investors tracking the company's financial trajectory.
The 8 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. have a median 12-month price target of $7, with estimates ranging from $6.5 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Maravai Lifesciences Holdings, Inc., 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maravai Lifesciences Holdings, Inc. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Maravai Lifesciences Holdings, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies -19.0% from the last close, and Ticker Nerd's factor model ranks Maravai Lifesciences Holdings, Inc. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Maravai Lifesciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $8 over the next 12 months.
Maravai Lifesciences Holdings, Inc. returned +261.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development.
The most recent item we track (Seeking Alpha, 7 Aug 2026): "Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript". Maravai LifeSciences Holdings, Inc. released its Q2 2026 earnings call transcript, covering the company's second-quarter 2026 financial results and management commentary. The transcript was published via Seeking Alpha.
Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development. The company's main are the production of nucleic acids and biologics, which are essential components in fields such as drug development, diagnostics, and molecular testing. Maravai is deeply involved in supplying innovative solutions for the synthesis and modification of nucleic acids, enabling breakthroughs in messenger RNA (mRNA) technology, a key area in the development of vaccines and therapies. The company's operations are integral to various industries where precision and cutting-edge biological research are paramount. Its contributions have been particularly impactful in accelerating the development of vaccines and treatments in response to the global demand for advanced biopharmaceutical solutions. With a strong commitment to supporting scientific innovation, Maravai Lifesciences Holdings Inc. holds a significant role in the life sciences market, providing foundational tools that empower researchers and healthcare institutions worldwide to achieve advancements in health and medicine.
CEO Mr. Bernd Brust · 415 employees · United States · https://www.maravai.com